Clinical evaluation of therapeutic cancer vaccines

Area of Science:

• Oncology
• Immunology
• Clinical Trials

Background:

• Therapeutic cancer vaccines are immunotherapies designed to stimulate an immune response against tumor antigens.
• Provenge® is the sole therapeutic cancer vaccine approved by the US FDA; however, approvals vary globally, with none by the European Medicines Agency (EMA).
• Many Phase III therapeutic cancer vaccine trials have failed to meet primary efficacy endpoints.

Purpose of the Study:

• To analyze the efficacy and failure points of therapeutic cancer vaccine Phase III studies.
• To investigate the role of tumor burden and immunological response as prognostic factors in therapeutic cancer vaccine efficacy.
• To identify strategies for improving the success rate of future therapeutic cancer vaccine clinical trials.

Main Methods:

• Retrospective analysis of 23 completed or terminated Phase III therapeutic cancer vaccine studies.
• Survey of reasons for failure in 13 of the 17 studies that did not meet primary endpoints.
• Examination of tumor burden reduction strategies and immunological response as predictive/prognostic factors.

Main Results:

• 74% (17/23) of Phase III studies failed to demonstrate significant primary endpoint efficacy.
• Despite tumor burden reduction efforts, 69% (9/13) of surveyed studies still failed, suggesting tumor burden is not the sole determinant of success.
• Immunological response has shown association with efficacy in subgroup analyses, indicating its potential as a key factor.

Conclusions:

• Therapeutic cancer vaccine trials face high failure rates, with tumor burden alone being an insufficient prognostic factor.
• Incorporating immunological response metrics alongside tumor stage in eligibility criteria or subgroup analyses could reduce heterogeneity and enhance Phase III study success.
• Further research into optimizing patient selection based on immunological profiles is crucial for advancing therapeutic cancer vaccine development.